Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
Paralysis is no longer for life, and this is just one of tens of new breakthrough innovations that’s making it possible to give people their lives back.
Paralysis used to be irreversible, but medical breakthroughs in the past couple of years have shown several times that, even in the most extreme cases, it’s possible to reverse. And now scientists in Germany have succeeded again, this time in getting paralysed mice to walk again with the key being the protein Hyper-Interleukin-6, HIL-6, which stimulates nerve cells to regenerate, and the way it is supplied to the animals.
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life.
In their search for potential therapeutic cures the Ruhr-Universität Bochum team has been working with the protein HIL-6.
Two weeks after treatment the mice are able to walk again
“This is a so called designer cytokine, a type of synthetic protein, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that HIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study the team induced nerve cells of the motor-sensory cortex to produce HIL-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult-to-access essential nerve cells and released there in a controlled manner.
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of HIL-6 further and achieve additional functional improvements. They are also exploring whether HIL-6 still has positive effects in mice, even if the injury occurred several weeks previously.
“This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The German Research Foundation funded the study.